JPH04502458A - レニン阻害性ペプチド類の経皮および鼻腔内投与 - Google Patents

レニン阻害性ペプチド類の経皮および鼻腔内投与

Info

Publication number: JPH04502458A
Authority: JP; Japan
Prior art keywords: pro; mehis; lva; peptide; ile
Prior art date: 1988-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2501323A

Other languages

English (en)

Japanese (ja)

Inventor

ポールズ，ドナルド・セオドア

オラノフ，ローレンス・エス

ローソン，ジュディー・アン

ギブソン，リチャード・アール

Original Assignee

ジ・アップジョン・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-22

Filing date

1989-12-01

Publication date

1992-05-07

1989-12-01 Application filed by ジ・アップジョン・カンパニー filed Critical ジ・アップジョン・カンパニー

1992-05-07 Publication of JPH04502458A publication Critical patent/JPH04502458A/ja

Status Pending legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 25
108090000783 Renin Proteins 0.000 title claims description 12
102100028255 Renin Human genes 0.000 title claims description 11
230000002401 inhibitory effect Effects 0.000 title claims description 9
102000004196 processed proteins & peptides Human genes 0.000 title description 7
108010026906 renin inhibitory peptide Proteins 0.000 claims description 14
241000124008 Mammalia Species 0.000 claims description 11
239000000203 mixture Substances 0.000 claims description 10
AIRMFERKNRDUKD-QLAANKDXSA-N (2s)-6-amino-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-2-[[1-[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]propanoyl]am Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)C1N(CCC1)C(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AIRMFERKNRDUKD-QLAANKDXSA-N 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
206010020772 Hypertension Diseases 0.000 claims description 6
150000001204 N-oxides Chemical class 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
230000037317 transdermal delivery Effects 0.000 claims description 5
210000003928 nasal cavity Anatomy 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 4
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
150000001875 compounds Chemical class 0.000 description 9
241000700159 Rattus Species 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
210000000609 ganglia Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
102000004881 Angiotensinogen Human genes 0.000 description 2
108090001067 Angiotensinogen Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
101000579218 Homo sapiens Renin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
230000006870 function Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
-1 Boc Chemical class 0.000 description 1
241000723347 Cinnamomum Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002315 pressor effect Effects 0.000 description 1
FOWDZVNRQHPXDO-UHFFFAOYSA-N propyl hydrogen carbonate Chemical compound CCCOC(O)=O FOWDZVNRQHPXDO-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000011269 tar Substances 0.000 description 1
238000013271 transdermal drug delivery Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

JP2501323A 1988-12-22 1989-12-01 レニン阻害性ペプチド類の経皮および鼻腔内投与 Pending JPH04502458A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28853188A	1988-12-22	1988-12-22
US288,531		1988-12-22

Publications (1)

Publication Number	Publication Date
JPH04502458A true JPH04502458A (ja)	1992-05-07

Family

ID=23107533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2501323A Pending JPH04502458A (ja)	1988-12-22	1989-12-01	レニン阻害性ペプチド類の経皮および鼻腔内投与

Country Status (5)

Country	Link
EP (1)	EP0449943A1 (de)
JP (1)	JPH04502458A (de)
AU (1)	AU4664089A (de)
CA (1)	CA2004571A1 (de)
WO (1)	WO1990006761A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19819652A1 (de) *	1998-05-02	1999-11-11	Lohmann Therapie Syst Lts	Therapeutisches System zur topischen oder transmucosalen Applikation wenigstens eines Pflege- oder Wirkstoffs auf bzw. durch die Nasenschleimhaut sowie Verfahren zur Applikation des Systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK356085A (da) *	1984-08-06	1986-02-07	Upjohn Co	Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
US4906613A (en) *	1985-11-05	1990-03-06	Schering Corporation	Antiglaucoma compositions and methods
US4758584A (en) *	1987-02-05	1988-07-19	Ciba-Geigy Corporation	Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups

1989
- 1989-12-01 WO PCT/US1989/005343 patent/WO1990006761A1/en not_active Ceased
- 1989-12-01 AU AU46640/89A patent/AU4664089A/en not_active Abandoned
- 1989-12-01 JP JP2501323A patent/JPH04502458A/ja active Pending
- 1989-12-01 EP EP90901256A patent/EP0449943A1/de not_active Withdrawn
- 1989-12-05 CA CA002004571A patent/CA2004571A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU4664089A (en)	1990-07-10
EP0449943A1 (de)	1991-10-09
CA2004571A1 (en)	1990-06-22
WO1990006761A1 (en)	1990-06-28

Publication	Publication Date	Title
JP2542620B2 (ja)	1996-10-09	Ａｃｅ阻害剤の抗高血圧活性を高める医薬組成物
US5807571A (en)	1998-09-15	Transdermal therapeutic systems for administering indole serotonin agonists
KR101186029B1 (ko)	2012-09-27	신경병증성 당뇨병성 족부 궤양을 치료하기 위한트레프로스티닐의 용도
EP0183527A2 (de)	1986-06-04	Absorbierbares Calcitoninarzneimittel
JPH0584286B2 (de)	1993-12-01
US20070264373A1 (en)	2007-11-15	Toxin Induced Sympathectomy
JPS61145121A (ja)	1986-07-02	ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤
JPH0233009B2 (de)	1990-07-25
JPH04502458A (ja)	1992-05-07	レニン阻害性ペプチド類の経皮および鼻腔内投与
US5006510A (en)	1991-04-09	Method for relieving chronic pain with a somatostatin analog composition
US20050118241A1 (en)	2005-06-02	Platform for transdermal formulations (ptf)
US5380710A (en)	1995-01-10	Pharmaceutical compositions containing ACTH (1-24) for the therapy of shock conditions and respiratory and cardiocirculatory insufficiences
KR101656324B1 (ko)	2016-09-09	키닌 ｂ２ 수용체 길항제 및 코르티코스테로이드에 기반한 약학적 조성물 및 그의 용도
US6841576B2 (en)	2005-01-11	Anti-hypertensive composition and methods of treatment
JP2000507207A (ja)	2000-06-13	複合注射剤
EA002023B1 (ru)	2001-12-24	Фармацевтическая композиция местного применения для введения в живой организм, содержащая пептидное лекарственное средство
EP0232697B1 (de)	1993-07-28	ACTH-Fragmente enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Schockzuständen sowie von respiratorischen und Herz-Kreislauf-Insuffizienzen
RU2007169C1 (ru)	1994-02-15	Средство, обладающее антигипертензивным действием
JPS6045161B2 (ja)	1985-10-08	熱傷の治療剤
KR20250135809A (ko)	2025-09-15	요독증성 소양증의 치료
JPS6041053B2 (ja)	1985-09-13	ペプチドホルモンの安定化剤
JPH0311022A (ja)	1991-01-18	薬剤組成物
JPH11292790A (ja)	1999-10-26	腎疾患治療剤
JPH04295419A (ja)	1992-10-20	吸収促進剤
HK1006283B (en)	1999-02-19	Pharmaceutical compositions containing acth fragments for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies